#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=The MDS-CVI is primarily a data-collection tool .
2-1	14-17	The	object[2]	new[2]	coref	2-4[3_2]
2-2	18-25	MDS-CVI	object[2]	new[2]	_	_
2-3	26-28	is	_	_	_	_
2-4	29-38	primarily	object[3]	giv[3]	coref	9-5[57_3]
2-5	39-40	a	object[3]	giv[3]	_	_
2-6	41-56	data-collection	object[3]	giv[3]	_	_
2-7	57-61	tool	object[3]	giv[3]	_	_
2-8	62-63	.	_	_	_	_

#Text=However , when completing the registry , healthcare professionals are reminded of important actions that can be carried out in people with risk factors such as older age , female sex , and obesity , which increase their likelihood of having CVD .
3-1	64-71	However	_	_	_	_
3-2	72-73	,	_	_	_	_
3-3	74-78	when	_	_	_	_
3-4	79-89	completing	_	_	_	_
3-5	90-93	the	abstract[4]	new[4]	_	_
3-6	94-102	registry	abstract[4]	new[4]	_	_
3-7	103-104	,	_	_	_	_
3-8	105-115	healthcare	organization|person[6]	new|new[6]	ana|coref|ana|coref	3-38[0_6]|5-1|3-38[0_6]|5-1
3-9	116-129	professionals	person[6]	new[6]	_	_
3-10	130-133	are	_	_	_	_
3-11	134-142	reminded	_	_	_	_
3-12	143-145	of	_	_	_	_
3-13	146-155	important	abstract[7]	new[7]	_	_
3-14	156-163	actions	abstract[7]	new[7]	_	_
3-15	164-168	that	_	_	_	_
3-16	169-172	can	_	_	_	_
3-17	173-175	be	_	_	_	_
3-18	176-183	carried	_	_	_	_
3-19	184-187	out	_	_	_	_
3-20	188-190	in	_	_	_	_
3-21	191-197	people	abstract[8]	new[8]	_	_
3-22	198-202	with	abstract[8]	new[8]	_	_
3-23	203-207	risk	abstract[8]|abstract|abstract[10]	new[8]|new|new[10]	_	_
3-24	208-215	factors	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-25	216-220	such	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-26	221-223	as	abstract[8]|abstract[10]	new[8]|new[10]	_	_
3-27	224-229	older	abstract[8]|abstract[10]|abstract[11]|abstract[12]	new[8]|new[10]|new[11]|new[12]	ana|ana	5-5[0_12]|5-5[0_12]
3-28	230-233	age	abstract[8]|abstract[10]|abstract[11]|abstract[12]	new[8]|new[10]|new[11]|new[12]	_	_
3-29	234-235	,	abstract[8]|abstract[10]|abstract[12]	new[8]|new[10]|new[12]	_	_
3-30	236-242	female	abstract[8]|abstract[10]|abstract[12]|abstract[13]	new[8]|new[10]|new[12]|new[13]	_	_
3-31	243-246	sex	abstract[8]|abstract[10]|abstract[12]|abstract[13]	new[8]|new[10]|new[12]|new[13]	_	_
3-32	247-248	,	abstract[8]|abstract[10]|abstract[12]	new[8]|new[10]|new[12]	_	_
3-33	249-252	and	abstract[8]|abstract[10]|abstract[12]	new[8]|new[10]|new[12]	_	_
3-34	253-260	obesity	abstract[8]|abstract[10]|abstract[12]|abstract	new[8]|new[10]|new[12]|new	coref	7-7[41_0]
3-35	261-262	,	_	_	_	_
3-36	263-268	which	_	_	_	_
3-37	269-277	increase	_	_	_	_
3-38	278-283	their	person|abstract[16]	giv|new[16]	coref|coref	5-1[26_0]|5-1[26_0]
3-39	284-294	likelihood	abstract[16]	new[16]	_	_
3-40	295-297	of	_	_	_	_
3-41	298-304	having	_	_	_	_
3-42	305-308	CVD	abstract	new	coref	4-7
3-43	309-310	.	_	_	_	_

#Text=Activities to promote health , prevent CVD , and diagnose it at earlier stages will help halt or delay disease progress .
4-1	311-321	Activities	abstract	new	_	_
4-2	322-324	to	_	_	_	_
4-3	325-332	promote	_	_	_	_
4-4	333-339	health	abstract	new	ana	4-11
4-5	340-341	,	_	_	_	_
4-6	342-349	prevent	_	_	_	_
4-7	350-353	CVD	event	giv	coref	6-6
4-8	354-355	,	_	_	_	_
4-9	356-359	and	_	_	_	_
4-10	360-368	diagnose	_	_	_	_
4-11	369-371	it	abstract	giv	coref	5-8[28_0]
4-12	372-374	at	_	_	_	_
4-13	375-382	earlier	abstract[22]	new[22]	coref	7-13[42_22]
4-14	383-389	stages	abstract[22]	new[22]	_	_
4-15	390-394	will	_	_	_	_
4-16	395-399	help	_	_	_	_
4-17	400-404	halt	_	_	_	_
4-18	405-407	or	_	_	_	_
4-19	408-413	delay	_	_	_	_
4-20	414-421	disease	abstract|abstract[24]	new|new[24]	_	_
4-21	422-430	progress	abstract[24]	new[24]	_	_
4-22	431-432	.	_	_	_	_

#Text=Healthcare professionals , and those working in primary health in particular , should aim to educate at-risk patients to lead a healthy lifestyle and use compression stockings .
5-1	433-443	Healthcare	organization|person[26]	giv|giv[26]	coref|coref|coref|coref	8-5|8-5[45_26]|8-5|8-5[45_26]
5-2	444-457	professionals	person[26]	giv[26]	_	_
5-3	458-459	,	_	_	_	_
5-4	460-463	and	_	_	_	_
5-5	464-469	those	abstract	giv	_	_
5-6	470-477	working	_	_	_	_
5-7	478-480	in	_	_	_	_
5-8	481-488	primary	abstract[28]	giv[28]	coref	9-10[0_28]
5-9	489-495	health	abstract[28]	giv[28]	_	_
5-10	496-498	in	_	_	_	_
5-11	499-509	particular	_	_	_	_
5-12	510-511	,	_	_	_	_
5-13	512-518	should	_	_	_	_
5-14	519-522	aim	_	_	_	_
5-15	523-525	to	_	_	_	_
5-16	526-533	educate	_	_	_	_
5-17	534-541	at-risk	abstract|person[30]	new|new[30]	coref|coref	9-8[58_30]|9-8[58_30]
5-18	542-550	patients	person[30]	new[30]	_	_
5-19	551-553	to	_	_	_	_
5-20	554-558	lead	_	_	_	_
5-21	559-560	a	abstract[31]	new[31]	_	_
5-22	561-568	healthy	abstract[31]	new[31]	_	_
5-23	569-578	lifestyle	abstract[31]	new[31]	_	_
5-24	579-582	and	_	_	_	_
5-25	583-586	use	_	_	_	_
5-26	587-598	compression	event|object[33]	new|new[33]	coref|coref|coref|coref	15-11[112_0]|15-43[125_33]|15-11[112_0]|15-43[125_33]
5-27	599-608	stockings	object[33]	new[33]	_	_
5-28	609-610	.	_	_	_	_

#Text=Due to increased awareness of CVD , the tendency is generally for earlier diagnosis and treatment .
6-1	611-614	Due	_	_	_	_
6-2	615-617	to	_	_	_	_
6-3	618-627	increased	abstract[34]	new[34]	_	_
6-4	628-637	awareness	abstract[34]	new[34]	_	_
6-5	638-640	of	abstract[34]	new[34]	_	_
6-6	641-644	CVD	abstract[34]|abstract	new[34]|giv	coref	21-12
6-7	645-646	,	_	_	_	_
6-8	647-650	the	abstract[36]	new[36]	_	_
6-9	651-659	tendency	abstract[36]	new[36]	_	_
6-10	660-662	is	_	_	_	_
6-11	663-672	generally	event[37]|event[38]	new[37]|new[38]	coref|coref|coref|coref	10-11[69_37]|10-11[70_38]|10-11[69_37]|10-11[70_38]
6-12	673-676	for	event[37]|event[38]	new[37]|new[38]	_	_
6-13	677-684	earlier	event[37]|event[38]	new[37]|new[38]	_	_
6-14	685-694	diagnosis	event[37]|event[38]	new[37]|new[38]	_	_
6-15	695-698	and	event[38]	new[38]	_	_
6-16	699-708	treatment	event[38]|event	new[38]|new	coref	10-14
6-17	709-710	.	_	_	_	_

#Text=However , in some countries , the disease is not detected until more advanced stages .
7-1	711-718	However	_	_	_	_
7-2	719-720	,	_	_	_	_
7-3	721-723	in	_	_	_	_
7-4	724-728	some	place[40]	new[40]	_	_
7-5	729-738	countries	place[40]	new[40]	_	_
7-6	739-740	,	_	_	_	_
7-7	741-744	the	abstract[41]	giv[41]	coref	9-22[0_41]
7-8	745-752	disease	abstract[41]	giv[41]	_	_
7-9	753-755	is	_	_	_	_
7-10	756-759	not	_	_	_	_
7-11	760-768	detected	_	_	_	_
7-12	769-774	until	_	_	_	_
7-13	775-779	more	abstract[42]	giv[42]	coref	13-31[95_42]
7-14	780-788	advanced	abstract[42]	giv[42]	_	_
7-15	789-795	stages	abstract[42]	giv[42]	_	_
7-16	796-797	.	_	_	_	_

#Text=There are gaps in healthcare professionals ’ knowledge of venous leg ulcer physiology and its healing process , partly due to a lack of training at a degree level .
8-1	798-803	There	_	_	_	_
8-2	804-807	are	_	_	_	_
8-3	808-812	gaps	abstract[43]	new[43]	_	_
8-4	813-815	in	abstract[43]	new[43]	_	_
8-5	816-826	healthcare	abstract[43]|organization|person[45]|abstract[46]	new[43]|giv|giv[45]|new[46]	coref|coref|coref|coref|coref|coref	9-13|9-13[62_45]|9-13|9-13[62_45]|9-13|9-13[62_45]
8-6	827-840	professionals	abstract[43]|person[45]|abstract[46]	new[43]|giv[45]|new[46]	_	_
8-7	841-842	’	abstract[43]|person[45]|abstract[46]	new[43]|giv[45]|new[46]	_	_
8-8	843-852	knowledge	abstract[43]|abstract[46]	new[43]|new[46]	_	_
8-9	853-855	of	abstract[43]|abstract[46]	new[43]|new[46]	_	_
8-10	856-862	venous	abstract[43]|abstract[46]|place|object[48]	new[43]|new[46]|new|new[48]	coref|coref	19-27|19-27
8-11	863-866	leg	abstract[43]|abstract[46]|object[48]	new[43]|new[46]|new[48]	_	_
8-12	867-872	ulcer	abstract[43]|abstract[46]|person|abstract[50]	new[43]|new[46]|new|new[50]	coref|coref	19-46|19-46
8-13	873-883	physiology	abstract[43]|abstract[46]|abstract[50]	new[43]|new[46]|new[50]	_	_
8-14	884-887	and	abstract[43]|abstract[46]	new[43]|new[46]	_	_
8-15	888-891	its	abstract[43]|abstract[46]|abstract[52]	new[43]|new[46]|new[52]	_	_
8-16	892-899	healing	abstract[43]|abstract[46]|object|abstract[52]	new[43]|new[46]|new|new[52]	_	_
8-17	900-907	process	abstract[43]|abstract[46]|abstract[52]	new[43]|new[46]|new[52]	_	_
8-18	908-909	,	_	_	_	_
8-19	910-916	partly	_	_	_	_
8-20	917-920	due	_	_	_	_
8-21	921-923	to	_	_	_	_
8-22	924-925	a	abstract[53]	new[53]	_	_
8-23	926-930	lack	abstract[53]	new[53]	_	_
8-24	931-933	of	abstract[53]	new[53]	_	_
8-25	934-942	training	abstract[53]|abstract	new[53]|new	_	_
8-26	943-945	at	abstract[53]	new[53]	_	_
8-27	946-947	a	abstract[53]|abstract[56]	new[53]|new[56]	ana	9-17[0_56]
8-28	948-954	degree	abstract[53]|abstract|abstract[56]	new[53]|new|new[56]	_	_
8-29	955-960	level	abstract[53]|abstract[56]	new[53]|new[56]	_	_
8-30	961-962	.	_	_	_	_

#Text=By applying and incorporating this MDS-CVI in patients ’ health records , healthcare professionals will find it easier to monitor the disease course at every stage .
9-1	963-965	By	_	_	_	_
9-2	966-974	applying	_	_	_	_
9-3	975-978	and	_	_	_	_
9-4	979-992	incorporating	_	_	_	_
9-5	993-997	this	object[57]	giv[57]	coref	14-3[99_57]
9-6	998-1005	MDS-CVI	object[57]	giv[57]	_	_
9-7	1006-1008	in	object[57]	giv[57]	_	_
9-8	1009-1017	patients	object[57]|person[58]|object[60]	giv[57]|giv[58]|new[60]	coref|coref	15-25[0_58]|15-25[0_58]
9-9	1018-1019	’	object[57]|person[58]|object[60]	giv[57]|giv[58]|new[60]	_	_
9-10	1020-1026	health	object[57]|abstract|object[60]	giv[57]|giv|new[60]	coref	16-6
9-11	1027-1034	records	object[57]|object[60]	giv[57]|new[60]	_	_
9-12	1035-1036	,	_	_	_	_
9-13	1037-1047	healthcare	organization|person[62]	giv|giv[62]	ana|coref|ana|coref	10-4[0_62]|21-14|10-4[0_62]|21-14
9-14	1048-1061	professionals	person[62]	giv[62]	_	_
9-15	1062-1066	will	_	_	_	_
9-16	1067-1071	find	_	_	_	_
9-17	1072-1074	it	abstract	giv	coref	13-11[88_0]
9-18	1075-1081	easier	_	_	_	_
9-19	1082-1084	to	_	_	_	_
9-20	1085-1092	monitor	_	_	_	_
9-21	1093-1096	the	abstract[65]	new[65]	_	_
9-22	1097-1104	disease	abstract|abstract[65]	giv|new[65]	coref	11-12[76_0]
9-23	1105-1111	course	abstract[65]	new[65]	_	_
9-24	1112-1114	at	_	_	_	_
9-25	1115-1120	every	abstract[66]	new[66]	_	_
9-26	1121-1126	stage	abstract[66]	new[66]	_	_
9-27	1127-1128	.	_	_	_	_

#Text=Above all , they should follow the recommendations to ensure correct diagnosis and treatment .
10-1	1129-1134	Above	_	_	_	_
10-2	1135-1138	all	_	_	_	_
10-3	1139-1140	,	_	_	_	_
10-4	1141-1145	they	person	giv	coref	21-14[176_0]
10-5	1146-1152	should	_	_	_	_
10-6	1153-1159	follow	_	_	_	_
10-7	1160-1163	the	abstract[68]	new[68]	coref	22-1[182_68]
10-8	1164-1179	recommendations	abstract[68]	new[68]	_	_
10-9	1180-1182	to	_	_	_	_
10-10	1183-1189	ensure	_	_	_	_
10-11	1190-1197	correct	event[69]|event[70]	giv[69]|giv[70]	coref|coref	11-16[77_69]|11-16[77_69]
10-12	1198-1207	diagnosis	event[69]|event[70]	giv[69]|giv[70]	_	_
10-13	1208-1211	and	event[70]	giv[70]	_	_
10-14	1212-1221	treatment	event[70]|event	giv[70]|giv	_	_
10-15	1222-1223	.	_	_	_	_

#Text=The CEAP classification system is a very easy method to classify venous disease and reach a reliable diagnosis of CVD/CVI in the population .
11-1	1224-1227	The	abstract[74]	new[74]	coref	11-6[75_74]
11-2	1228-1232	CEAP	organization|abstract[74]	new|new[74]	_	_
11-3	1233-1247	classification	abstract|abstract[74]	new|new[74]	_	_
11-4	1248-1254	system	abstract[74]	new[74]	_	_
11-5	1255-1257	is	_	_	_	_
11-6	1258-1259	a	abstract[75]	giv[75]	coref	12-5[80_75]
11-7	1260-1264	very	abstract[75]	giv[75]	_	_
11-8	1265-1269	easy	abstract[75]	giv[75]	_	_
11-9	1270-1276	method	abstract[75]	giv[75]	_	_
11-10	1277-1279	to	_	_	_	_
11-11	1280-1288	classify	_	_	_	_
11-12	1289-1295	venous	abstract[76]	giv[76]	coref	14-22[0_76]
11-13	1296-1303	disease	abstract[76]	giv[76]	_	_
11-14	1304-1307	and	_	_	_	_
11-15	1308-1313	reach	_	_	_	_
11-16	1314-1315	a	event[77]	giv[77]	_	_
11-17	1316-1324	reliable	event[77]	giv[77]	_	_
11-18	1325-1334	diagnosis	event[77]	giv[77]	_	_
11-19	1335-1337	of	event[77]	giv[77]	_	_
11-20	1338-1345	CVD/CVI	event[77]|abstract	giv[77]|new	_	_
11-21	1346-1348	in	_	_	_	_
11-22	1349-1352	the	person[79]	new[79]	coref	13-8[87_79]
11-23	1353-1363	population	person[79]	new[79]	_	_
11-24	1364-1365	.	_	_	_	_

#Text=The clinical part of the system can be obtained simply by observing a patient ’s legs in the primary care setting .
12-1	1366-1369	The	_	_	_	_
12-2	1370-1378	clinical	_	_	_	_
12-3	1379-1383	part	_	_	_	_
12-4	1384-1386	of	_	_	_	_
12-5	1387-1390	the	abstract[80]	giv[80]	_	_
12-6	1391-1397	system	abstract[80]	giv[80]	_	_
12-7	1398-1401	can	_	_	_	_
12-8	1402-1404	be	_	_	_	_
12-9	1405-1413	obtained	_	_	_	_
12-10	1414-1420	simply	_	_	_	_
12-11	1421-1423	by	_	_	_	_
12-12	1424-1433	observing	_	_	_	_
12-13	1434-1435	a	object[82]	new[82]	_	_
12-14	1436-1443	patient	person[81]|object[82]	new[81]|new[82]	_	_
12-15	1444-1446	’s	person[81]|object[82]	new[81]|new[82]	_	_
12-16	1447-1451	legs	object[82]	new[82]	_	_
12-17	1452-1454	in	object[82]	new[82]	_	_
12-18	1455-1458	the	object[82]|place[84]	new[82]|new[84]	ana	13-1[0_84]
12-19	1459-1466	primary	object[82]|place[84]	new[82]|new[84]	_	_
12-20	1467-1471	care	object[82]|abstract|place[84]	new[82]|new|new[84]	coref	23-8
12-21	1472-1479	setting	object[82]|place[84]	new[82]|new[84]	_	_
12-22	1480-1481	.	_	_	_	_

#Text=It is estimated that 80 % of the population have the mildest level of symptoms ( C1 – C2 , spider and varicose veins ) , while 5 % have the most advanced stages ( C3 – C6 ) .
13-1	1482-1484	It	place	giv	_	_
13-2	1485-1487	is	_	_	_	_
13-3	1488-1497	estimated	_	_	_	_
13-4	1498-1502	that	_	_	_	_
13-5	1503-1505	80	quantity[86]	new[86]	_	_
13-6	1506-1507	%	quantity[86]	new[86]	_	_
13-7	1508-1510	of	quantity[86]	new[86]	_	_
13-8	1511-1514	the	quantity[86]|person[87]	new[86]|giv[87]	coref	14-17[103_87]
13-9	1515-1525	population	quantity[86]|person[87]	new[86]|giv[87]	_	_
13-10	1526-1530	have	_	_	_	_
13-11	1531-1534	the	abstract[88]	giv[88]	_	_
13-12	1535-1542	mildest	abstract[88]	giv[88]	_	_
13-13	1543-1548	level	abstract[88]	giv[88]	_	_
13-14	1549-1551	of	abstract[88]	giv[88]	_	_
13-15	1552-1560	symptoms	abstract[88]|abstract	giv[88]|new	appos	13-17[90_0]
13-16	1561-1562	(	_	_	_	_
13-17	1563-1565	C1	abstract[90]	giv[90]	appos	13-21[0_90]
13-18	1566-1567	–	abstract[90]	giv[90]	_	_
13-19	1568-1570	C2	abstract[90]|abstract	giv[90]|new	_	_
13-20	1571-1572	,	_	_	_	_
13-21	1573-1579	spider	abstract	giv	_	_
13-22	1580-1583	and	_	_	_	_
13-23	1584-1592	varicose	object[93]	new[93]	_	_
13-24	1593-1598	veins	object[93]	new[93]	_	_
13-25	1599-1600	)	_	_	_	_
13-26	1601-1602	,	_	_	_	_
13-27	1603-1608	while	_	_	_	_
13-28	1609-1610	5	quantity[94]	new[94]	_	_
13-29	1611-1612	%	quantity[94]	new[94]	_	_
13-30	1613-1617	have	_	_	_	_
13-31	1618-1621	the	abstract[95]	giv[95]	ana	14-30[0_95]
13-32	1622-1626	most	abstract[95]	giv[95]	_	_
13-33	1627-1635	advanced	abstract[95]	giv[95]	_	_
13-34	1636-1642	stages	abstract[95]	giv[95]	_	_
13-35	1643-1644	(	_	_	_	_
13-36	1645-1647	C3	abstract[96]	new[96]	_	_
13-37	1648-1649	–	abstract[96]	new[96]	_	_
13-38	1650-1652	C6	abstract[96]|abstract	new[96]|new	_	_
13-39	1653-1654	)	_	_	_	_
13-40	1655-1656	.	_	_	_	_

#Text=Implementation of this evidence-based MDS-CVI would result in more reliable data collection and facilitate monitoring of a specific population to observe disease progression , the treatments used , and their effectiveness .
14-1	1657-1671	Implementation	abstract[98]	new[98]	_	_
14-2	1672-1674	of	abstract[98]	new[98]	_	_
14-3	1675-1679	this	abstract[98]|object[99]	new[98]|giv[99]	coref	16-1[126_99]
14-4	1680-1694	evidence-based	abstract[98]|object[99]	new[98]|giv[99]	_	_
14-5	1695-1702	MDS-CVI	abstract[98]|object[99]	new[98]|giv[99]	_	_
14-6	1703-1708	would	_	_	_	_
14-7	1709-1715	result	_	_	_	_
14-8	1716-1718	in	_	_	_	_
14-9	1719-1723	more	abstract[101]	new[101]	_	_
14-10	1724-1732	reliable	abstract[101]	new[101]	_	_
14-11	1733-1737	data	abstract|abstract[101]	new|new[101]	_	_
14-12	1738-1748	collection	abstract[101]	new[101]	_	_
14-13	1749-1752	and	_	_	_	_
14-14	1753-1763	facilitate	_	_	_	_
14-15	1764-1774	monitoring	event[102]	new[102]	_	_
14-16	1775-1777	of	event[102]	new[102]	_	_
14-17	1778-1779	a	event[102]|person[103]	new[102]|giv[103]	coref	16-17[131_103]
14-18	1780-1788	specific	event[102]|person[103]	new[102]|giv[103]	_	_
14-19	1789-1799	population	event[102]|person[103]	new[102]|giv[103]	_	_
14-20	1800-1802	to	_	_	_	_
14-21	1803-1810	observe	_	_	_	_
14-22	1811-1818	disease	abstract|abstract[105]	giv|new[105]	appos|coref|appos|coref	14-25[106_105]|18-8[140_0]|14-25[106_105]|18-8[140_0]
14-23	1819-1830	progression	abstract[105]	new[105]	_	_
14-24	1831-1832	,	_	_	_	_
14-25	1833-1836	the	abstract[106]	giv[106]	coref	22-16[188_106]
14-26	1837-1847	treatments	abstract[106]	giv[106]	_	_
14-27	1848-1852	used	_	_	_	_
14-28	1853-1854	,	_	_	_	_
14-29	1855-1858	and	_	_	_	_
14-30	1859-1864	their	abstract|abstract[108]	giv|new[108]	_	_
14-31	1865-1878	effectiveness	abstract[108]	new[108]	_	_
14-32	1879-1880	.	_	_	_	_

#Text=With the existing level of evidence of the importance of therapeutic compression of the lower limbs , it is unacceptable that 90 % of patients with CVI in Turkey and 54 % of patients with venous ulcers in Spain are not given compression stockings .
15-1	1881-1885	With	_	_	_	_
15-2	1886-1889	the	abstract[109]	new[109]	_	_
15-3	1890-1898	existing	abstract[109]	new[109]	_	_
15-4	1899-1904	level	abstract[109]	new[109]	_	_
15-5	1905-1907	of	abstract[109]	new[109]	_	_
15-6	1908-1916	evidence	abstract[109]|abstract[110]	new[109]|new[110]	_	_
15-7	1917-1919	of	abstract[109]|abstract[110]	new[109]|new[110]	_	_
15-8	1920-1923	the	abstract[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	ana	15-18[0_111]
15-9	1924-1934	importance	abstract[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
15-10	1935-1937	of	abstract[109]|abstract[110]|abstract[111]	new[109]|new[110]|new[111]	_	_
15-11	1938-1949	therapeutic	abstract[109]|abstract[110]|abstract[111]|event[112]	new[109]|new[110]|new[111]|giv[112]	coref	15-43[0_112]
15-12	1950-1961	compression	abstract[109]|abstract[110]|abstract[111]|event[112]	new[109]|new[110]|new[111]|giv[112]	_	_
15-13	1962-1964	of	abstract[109]|abstract[110]|abstract[111]|event[112]	new[109]|new[110]|new[111]|giv[112]	_	_
15-14	1965-1968	the	abstract[109]|abstract[110]|abstract[111]|event[112]|object[113]	new[109]|new[110]|new[111]|giv[112]|new[113]	_	_
15-15	1969-1974	lower	abstract[109]|abstract[110]|abstract[111]|event[112]|object[113]	new[109]|new[110]|new[111]|giv[112]|new[113]	_	_
15-16	1975-1980	limbs	abstract[109]|abstract[110]|abstract[111]|event[112]|object[113]	new[109]|new[110]|new[111]|giv[112]|new[113]	_	_
15-17	1981-1982	,	_	_	_	_
15-18	1983-1985	it	abstract	giv	_	_
15-19	1986-1988	is	_	_	_	_
15-20	1989-2001	unacceptable	_	_	_	_
15-21	2002-2006	that	person[123]	new[123]	_	_
15-22	2007-2009	90	quantity[115]|person[123]	new[115]|new[123]	_	_
15-23	2010-2011	%	quantity[115]|person[123]	new[115]|new[123]	_	_
15-24	2012-2014	of	quantity[115]|person[123]	new[115]|new[123]	_	_
15-25	2015-2023	patients	quantity[115]|person|person[123]	new[115]|giv|new[123]	coref	15-34[120_0]
15-26	2024-2028	with	quantity[115]|person[123]	new[115]|new[123]	_	_
15-27	2029-2032	CVI	quantity[115]|abstract[117]|person[123]	new[115]|new[117]|new[123]	coref	17-3[0_117]
15-28	2033-2035	in	quantity[115]|abstract[117]|person[123]	new[115]|new[117]|new[123]	_	_
15-29	2036-2042	Turkey	quantity[115]|abstract[117]|place|person[123]	new[115]|new[117]|new|new[123]	_	_
15-30	2043-2046	and	person[123]	new[123]	_	_
15-31	2047-2049	54	quantity[119]|person[123]	new[119]|new[123]	_	_
15-32	2050-2051	%	quantity[119]|person[123]	new[119]|new[123]	_	_
15-33	2052-2054	of	quantity[119]|person[123]	new[119]|new[123]	_	_
15-34	2055-2063	patients	quantity[119]|person[120]|person[123]	new[119]|giv[120]|new[123]	coref	19-11[144_120]
15-35	2064-2068	with	quantity[119]|person[120]|person[123]	new[119]|giv[120]|new[123]	_	_
15-36	2069-2075	venous	quantity[119]|person[120]|object[121]|person[123]	new[119]|giv[120]|new[121]|new[123]	coref	19-51[164_121]
15-37	2076-2082	ulcers	quantity[119]|person[120]|object[121]|person[123]	new[119]|giv[120]|new[121]|new[123]	_	_
15-38	2083-2085	in	quantity[119]|person[120]|object[121]|person[123]	new[119]|giv[120]|new[121]|new[123]	_	_
15-39	2086-2091	Spain	quantity[119]|person[120]|object[121]|place|person[123]	new[119]|giv[120]|new[121]|new|new[123]	coref	16-13[130_0]
15-40	2092-2095	are	person[123]	new[123]	_	_
15-41	2096-2099	not	person[123]	new[123]	_	_
15-42	2100-2105	given	person[123]	new[123]	_	_
15-43	2106-2117	compression	person[123]|event|object[125]	new[123]|giv|giv[125]	_	_
15-44	2118-2127	stockings	person[123]|object[125]	new[123]|giv[125]	_	_
15-45	2128-2129	.	_	_	_	_

#Text=The MDS-CVI will also permit health managers to plan interventions according to the venous state of the population and identify which quality indicators should be applied .
16-1	2130-2133	The	abstract[126]	giv[126]	_	_
16-2	2134-2141	MDS-CVI	abstract[126]	giv[126]	_	_
16-3	2142-2146	will	_	_	_	_
16-4	2147-2151	also	_	_	_	_
16-5	2152-2158	permit	_	_	_	_
16-6	2159-2165	health	abstract|person[128]	giv|new[128]	_	_
16-7	2166-2174	managers	person[128]	new[128]	_	_
16-8	2175-2177	to	_	_	_	_
16-9	2178-2182	plan	_	_	_	_
16-10	2183-2196	interventions	event[129]	new[129]	_	_
16-11	2197-2206	according	event[129]	new[129]	_	_
16-12	2207-2209	to	event[129]	new[129]	_	_
16-13	2210-2213	the	event[129]|place[130]	new[129]|giv[130]	_	_
16-14	2214-2220	venous	event[129]|place[130]	new[129]|giv[130]	_	_
16-15	2221-2226	state	event[129]|place[130]	new[129]|giv[130]	_	_
16-16	2227-2229	of	event[129]|place[130]	new[129]|giv[130]	_	_
16-17	2230-2233	the	event[129]|place[130]|person[131]	new[129]|giv[130]|giv[131]	_	_
16-18	2234-2244	population	event[129]|place[130]|person[131]	new[129]|giv[130]|giv[131]	_	_
16-19	2245-2248	and	_	_	_	_
16-20	2249-2257	identify	_	_	_	_
16-21	2258-2263	which	_	_	_	_
16-22	2264-2271	quality	abstract|abstract[133]	new|new[133]	coref|coref	17-5[136_0]|17-5[136_0]
16-23	2272-2282	indicators	abstract[133]	new[133]	_	_
16-24	2283-2289	should	_	_	_	_
16-25	2290-2292	be	_	_	_	_
16-26	2293-2300	applied	_	_	_	_
16-27	2301-2302	.	_	_	_	_

#Text=People with CVI have a poor quality of life .
17-1	2303-2309	People	person[134]	new[134]	_	_
17-2	2310-2314	with	person[134]	new[134]	_	_
17-3	2315-2318	CVI	person[134]|abstract	new[134]|giv	coref	19-39
17-4	2319-2323	have	_	_	_	_
17-5	2324-2325	a	abstract[136]	giv[136]	_	_
17-6	2326-2330	poor	abstract[136]	giv[136]	_	_
17-7	2331-2338	quality	abstract[136]	giv[136]	_	_
17-8	2339-2341	of	abstract[136]	giv[136]	_	_
17-9	2342-2346	life	abstract[136]|abstract	giv[136]|new	coref	19-9[143_0]
17-10	2347-2348	.	_	_	_	_

#Text=It is therefore important to determine how the venous disease affects each individual .
18-1	2349-2351	It	abstract	new	cata	18-1[0_139]
18-2	2352-2354	is	_	_	_	_
18-3	2355-2364	therefore	_	_	_	_
18-4	2365-2374	important	_	_	_	_
18-5	2375-2377	to	abstract[139]	new[139]	_	_
18-6	2378-2387	determine	abstract[139]	new[139]	_	_
18-7	2388-2391	how	abstract[139]	new[139]	_	_
18-8	2392-2395	the	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
18-9	2396-2402	venous	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
18-10	2403-2410	disease	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
18-11	2411-2418	affects	abstract[139]	new[139]	_	_
18-12	2419-2423	each	abstract[139]	new[139]	_	_
18-13	2424-2434	individual	abstract[139]	new[139]	_	_
18-14	2435-2436	.	_	_	_	_

#Text=Specific instruments are available to measure quality of life in these patients , such as the Aberdeen Varicose Vein Questionnaire ( AVVQ ) or the Chronic Venous Insufficiency Quality of Life Questionnaire ( CIVIC ) for patients with CVI , and the Charing Cross Venous Ulcer Questionnaire for patients with venous ulcers .
19-1	2437-2445	Specific	object[141]	new[141]	coref	20-1[165_141]
19-2	2446-2457	instruments	object[141]	new[141]	_	_
19-3	2458-2461	are	_	_	_	_
19-4	2462-2471	available	_	_	_	_
19-5	2472-2474	to	_	_	_	_
19-6	2475-2482	measure	_	_	_	_
19-7	2483-2490	quality	abstract[142]	new[142]	_	_
19-8	2491-2493	of	abstract[142]	new[142]	_	_
19-9	2494-2498	life	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
19-10	2499-2501	in	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
19-11	2502-2507	these	abstract[142]|abstract[143]|person[144]	new[142]|giv[143]|giv[144]	coref	19-37[157_144]
19-12	2508-2516	patients	abstract[142]|abstract[143]|person[144]	new[142]|giv[143]|giv[144]	_	_
19-13	2517-2518	,	abstract[142]	new[142]	_	_
19-14	2519-2523	such	abstract[142]	new[142]	_	_
19-15	2524-2526	as	abstract[142]	new[142]	_	_
19-16	2527-2530	the	abstract[142]|abstract[148]	new[142]|new[148]	appos	19-22[0_148]
19-17	2531-2539	Aberdeen	abstract[142]|place|abstract[148]	new[142]|new|new[148]	_	_
19-18	2540-2548	Varicose	abstract[142]|animal|abstract[148]	new[142]|new|new[148]	_	_
19-19	2549-2553	Vein	abstract[142]|plant|abstract[148]	new[142]|new|new[148]	_	_
19-20	2554-2567	Questionnaire	abstract[142]|abstract[148]	new[142]|new[148]	_	_
19-21	2568-2569	(	_	_	_	_
19-22	2570-2574	AVVQ	abstract	giv	coref	19-31[155_0]
19-23	2575-2576	)	_	_	_	_
19-24	2577-2579	or	_	_	_	_
19-25	2580-2583	the	abstract[153]	new[153]	coref	23-7[0_153]
19-26	2584-2591	Chronic	person|abstract[153]	new|new[153]	_	_
19-27	2592-2598	Venous	person|abstract[153]	giv|new[153]	coref	19-45
19-28	2599-2612	Insufficiency	abstract|abstract[153]	new|new[153]	_	_
19-29	2613-2620	Quality	abstract[153]	new[153]	_	_
19-30	2621-2623	of	abstract[153]	new[153]	_	_
19-31	2624-2628	Life	abstract[153]|time|abstract[155]	new[153]|new|giv[155]	coref|coref	19-42[163_155]|19-42[163_155]
19-32	2629-2642	Questionnaire	abstract[153]|abstract[155]	new[153]|giv[155]	_	_
19-33	2643-2644	(	_	_	_	_
19-34	2645-2650	CIVIC	object	new	_	_
19-35	2651-2652	)	_	_	_	_
19-36	2653-2656	for	_	_	_	_
19-37	2657-2665	patients	person[157]	giv[157]	_	_
19-38	2666-2670	with	person[157]	giv[157]	_	_
19-39	2671-2674	CVI	person[157]|abstract	giv[157]|giv	coref	23-4
19-40	2675-2676	,	person[157]	giv[157]	_	_
19-41	2677-2680	and	person[157]	giv[157]	_	_
19-42	2681-2684	the	person[157]|abstract[163]	giv[157]|giv[163]	_	_
19-43	2685-2692	Charing	person[157]|abstract|abstract[163]	giv[157]|new|giv[163]	_	_
19-44	2693-2698	Cross	person[157]|person|abstract[163]	giv[157]|new|giv[163]	_	_
19-45	2699-2705	Venous	person[157]|person|abstract[163]	giv[157]|giv|giv[163]	coref	22-12
19-46	2706-2711	Ulcer	person[157]|person|abstract[163]	giv[157]|giv|giv[163]	_	_
19-47	2712-2725	Questionnaire	person[157]|abstract[163]	giv[157]|giv[163]	_	_
19-48	2726-2729	for	person[157]|abstract[163]	giv[157]|giv[163]	_	_
19-49	2730-2738	patients	person[157]|abstract[163]	giv[157]|giv[163]	_	_
19-50	2739-2743	with	person[157]|abstract[163]	giv[157]|giv[163]	_	_
19-51	2744-2750	venous	person[157]|abstract[163]|object[164]	giv[157]|giv[163]|giv[164]	_	_
19-52	2751-2757	ulcers	person[157]|abstract[163]|object[164]	giv[157]|giv[163]|giv[164]	_	_
19-53	2758-2759	.	_	_	_	_

#Text=The instruments are valid for only certain languages and cultures and they therefore need to be adapted to be effective .
20-1	2760-2763	The	object[165]	giv[165]	_	_
20-2	2764-2775	instruments	object[165]	giv[165]	_	_
20-3	2776-2779	are	_	_	_	_
20-4	2780-2785	valid	_	_	_	_
20-5	2786-2789	for	_	_	_	_
20-6	2790-2794	only	abstract[166]	new[166]	_	_
20-7	2795-2802	certain	abstract[166]	new[166]	_	_
20-8	2803-2812	languages	abstract[166]	new[166]	_	_
20-9	2813-2816	and	_	_	_	_
20-10	2817-2825	cultures	abstract	new	ana	20-12
20-11	2826-2829	and	_	_	_	_
20-12	2830-2834	they	abstract	giv	_	_
20-13	2835-2844	therefore	_	_	_	_
20-14	2845-2849	need	_	_	_	_
20-15	2850-2852	to	_	_	_	_
20-16	2853-2855	be	_	_	_	_
20-17	2856-2863	adapted	_	_	_	_
20-18	2864-2866	to	_	_	_	_
20-19	2867-2869	be	_	_	_	_
20-20	2870-2879	effective	_	_	_	_
20-21	2880-2881	.	_	_	_	_

#Text=Non-pharmacological measures are essential in the prevention and adjuvant therapy of CVD and healthcare professionals should therefore be aware of their existence and use them in their clinical practice .
21-1	2882-2901	Non-pharmacological	abstract[169]	new[169]	_	_
21-2	2902-2910	measures	abstract[169]	new[169]	_	_
21-3	2911-2914	are	_	_	_	_
21-4	2915-2924	essential	_	_	_	_
21-5	2925-2927	in	_	_	_	_
21-6	2928-2931	the	abstract[170]|abstract[171]	new[170]|new[171]	ana|ana	21-21[0_171]|21-21[0_171]
21-7	2932-2942	prevention	abstract[170]|abstract[171]	new[170]|new[171]	_	_
21-8	2943-2946	and	abstract[171]	new[171]	_	_
21-9	2947-2955	adjuvant	abstract[171]|abstract|abstract[173]	new[171]|new|new[173]	_	_
21-10	2956-2963	therapy	abstract[171]|abstract[173]	new[171]|new[173]	_	_
21-11	2964-2966	of	abstract[171]|abstract[173]	new[171]|new[173]	_	_
21-12	2967-2970	CVD	abstract[171]|abstract[173]|event	new[171]|new[173]|giv	_	_
21-13	2971-2974	and	_	_	_	_
21-14	2975-2985	healthcare	organization|person[176]	giv|giv[176]	_	_
21-15	2986-2999	professionals	person[176]	giv[176]	_	_
21-16	3000-3006	should	_	_	_	_
21-17	3007-3016	therefore	_	_	_	_
21-18	3017-3019	be	_	_	_	_
21-19	3020-3025	aware	_	_	_	_
21-20	3026-3028	of	_	_	_	_
21-21	3029-3034	their	abstract|abstract[178]	giv|new[178]	ana|ana	21-25|21-25
21-22	3035-3044	existence	abstract[178]	new[178]	_	_
21-23	3045-3048	and	_	_	_	_
21-24	3049-3052	use	_	_	_	_
21-25	3053-3057	them	abstract	giv	ana	21-27
21-26	3058-3060	in	_	_	_	_
21-27	3061-3066	their	abstract|abstract[181]	giv|new[181]	_	_
21-28	3067-3075	clinical	abstract[181]	new[181]	_	_
21-29	3076-3084	practice	abstract[181]	new[181]	_	_
21-30	3085-3086	.	_	_	_	_

#Text=Recommendations such as weight loss or taking regular exercise will help venous return and delay symptom progression .
22-1	3087-3102	Recommendations	abstract[182]	giv[182]	_	_
22-2	3103-3107	such	abstract[182]	giv[182]	_	_
22-3	3108-3110	as	abstract[182]	giv[182]	_	_
22-4	3111-3117	weight	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
22-5	3118-3122	loss	abstract[182]|abstract[183]	giv[182]|new[183]	_	_
22-6	3123-3125	or	_	_	_	_
22-7	3126-3132	taking	_	_	_	_
22-8	3133-3140	regular	event[184]	new[184]	_	_
22-9	3141-3149	exercise	event[184]	new[184]	_	_
22-10	3150-3154	will	_	_	_	_
22-11	3155-3159	help	_	_	_	_
22-12	3160-3166	venous	quantity|event[186]	giv|new[186]	_	_
22-13	3167-3173	return	event[186]	new[186]	_	_
22-14	3174-3177	and	_	_	_	_
22-15	3178-3183	delay	_	_	_	_
22-16	3184-3191	symptom	abstract|abstract[188]	new|giv[188]	_	_
22-17	3192-3203	progression	abstract[188]	giv[188]	_	_
22-18	3204-3205	.	_	_	_	_

#Text=The MDS for CVI establishes minimum quality care criteria and can help to guide in the purchase of necessary services .
23-1	3206-3209	The	abstract[189]	new[189]	_	_
23-2	3210-3213	MDS	abstract[189]	new[189]	_	_
23-3	3214-3217	for	abstract[189]	new[189]	_	_
23-4	3218-3221	CVI	abstract[189]|organization	new[189]|giv	_	_
23-5	3222-3233	establishes	_	_	_	_
23-6	3234-3241	minimum	abstract[193]	new[193]	_	_
23-7	3242-3249	quality	abstract|abstract[193]	giv|new[193]	_	_
23-8	3250-3254	care	abstract|abstract[193]	giv|new[193]	_	_
23-9	3255-3263	criteria	abstract[193]	new[193]	_	_
23-10	3264-3267	and	_	_	_	_
23-11	3268-3271	can	_	_	_	_
23-12	3272-3276	help	_	_	_	_
23-13	3277-3279	to	_	_	_	_
23-14	3280-3285	guide	_	_	_	_
23-15	3286-3288	in	_	_	_	_
23-16	3289-3292	the	event[194]	new[194]	_	_
23-17	3293-3301	purchase	event[194]	new[194]	_	_
23-18	3302-3304	of	event[194]	new[194]	_	_
23-19	3305-3314	necessary	event[194]|abstract[195]	new[194]|new[195]	_	_
23-20	3315-3323	services	event[194]|abstract[195]	new[194]|new[195]	_	_
23-21	3324-3325	.	_	_	_	_
